Analgesic Efficacy of Adding Sciatic Blockade to the 3-in-1 Block Following Total Knee Arthroplasty: A Meta-analysis
Abstract
Background: Total knee arthroplasty (TKA) is one of the most common orthopedic procedures performed. It is also invasive and is associated with severe postoperative pain. The 3-in-1 block has been repeatedly demonstrated to provide effective postoperative analgesia. However, adding sciatic blockade to the 3-in-1 has become a growing practice as a result of residual pain to the posterior knee, although the additional benefit is unknown particularly in light of the potential risks. Purpose: To examine the analgesic efficacy and associated adverse events of adding sciatic blockade to the 3-in-1 block compared to the 3-in-1 alone for postoperative analgesia following TKA. Methods: A meta-analysis was conducted on relevant articles from 1993 to 2010. Methodological rigor was applied to each of the analytical procedures including: evaluation of between-study heterogeneity, pooling effects, subgroup analyses, sensitivity analysis, and assessment of publication bias. Results: Nine studies representing 1827 subjects were included. Pain outcomes were measured with the visual analog scale both at rest (VASr) and dynamic (VASd) and reported as the weighted mean difference (WMD). The addition of sciatic blockade demonstrated improved postoperative analgesia with the greatest effects up to 24 hours postoperatively: early (6-8hr) VASr WMD -2.039 (95% CI: -2.718, -1.360); 12hr VASr WMD -1.491 (95% CI: -2.174, -0.808); 24hr VASr WMD -0.767 (95% CI: -1.114, -0.421); 24hr VASd WMD -0.671 (95% CI: -1.301, -0.041). The 24hr opioid consumption was also lower [WMD -10.237 (95% CI: -20.029, -0.444)]. After 24 hours, effects were small and/or not significant. There was also a statistically significant advantage in maximum knee flexion on POD3 [WMD -7.102 (95% CI: -11.864, -2.339)]. A lack of consistent reporting precluded quantitative analysis on adverse events. Conclusion: Findings support the use of peripheral nerve blocks for postoperative analgesia following TKA. The addition of sciatic blockade appears to offer greater analgesic efficacy than a 3-in-1 block alone but only in the early postoperative period. However, until an accurate estimate of associated adverse events can be unveiled, the addition of a sciatic block cannot be recommended for all patients following TKA. It should, however, be considered in the postoperative period for those patients who continue to experience substantial pain to the posterior aspect of the knee on a case-by-case basis.Description
University of Maryland, Baltimore. Nursing. Ph.D. 2010Keyword
3-in-1 nerve blockfemoral nerve block
peripheral nerve block
postoperative analgesia
sciatic nerve block
total knee arthroplasty
Arthroplasty, Replacement, Knee
Nerve Block
Pain, Postoperative
Identifier to cite or link to this item
http://hdl.handle.net/10713/894Related items
Showing items related by title, author, creator and subject.
-
Dexamethasone or Dexmedetomidine Adjuvants to Peripheral Nerve Blocks for Total Knee ReplacementFitzsimmons, Dean A.; Conley, Richard P. (2023-05)Problem and Purpose: At a community hospital, Total Knee Arthroplasties (TKAs) comprise 6.5% of all scheduled procedures, approximately 40 per month. Adequate postoperative pain control is critical for avoiding complications. The adductor canal block (ACB) and the interspace between the popliteal artery and capsule of the knee (IPACK) peripheral nerve blocks (PNBs) control postoperative pain; however, they only last 12–18 hours. Addition of dexamethasone or dexmedetomidine to local anesthetics used for PNBs have been identified to prolong their duration and improve postoperative pain control. The purpose of this project was to implement a guideline on additions of dexamethasone or dexmedetomidine to ACB and IPACK PNBs for TKAs to prolong the PNB for pain control. Methods: A guideline regarding use of dexamethasone and dexmedetomidine was created with input from anesthesia leadership. The anesthesia staff were educated during a staff meeting, the guideline was posted in operating rooms, and staff started adding either adjunct medication to the local anesthetic used for PNBs for TKAs. Over a 15-week period, compliance with the guideline was measured, along with pain scores in the post anesthesia care unit, 8, 16, 24 hours, or until discharge after a 23-hour observation. Data was collected weekly and analyzed using a run chart and descriptive statistics. Exclusion criteria were revision TKA, anxiety or depression on medication, and chronic pain on home opioids. Results: 94 patients were included. 38.9% of patients receiving PNBs had dexamethasone added (n=37). No PNBs used dexmedetomidine. 61.1% of PNBs did not have any adjunct added (n=58). 30.8% of patients had severe pain scores postoperatively (n=29). 24.2% of patients with severe pain had dexamethasone added (n=7). Median compliance with guideline use was 28%. Conclusions: There was no association with the implementation of the guideline and increased use of adjunct medications. Patients who received dexamethasone hadless incidence of severe pain. Addition of dexamethasone to PNBs is a low-cost way to improve pain scores postoperatively. Less severe pain scores improve patient satisfaction and removes a barrier to mobilization, reducing incidence of postoperative complications.
-
Retinoids and retinoic acid metabolism blocking agents in combination with histone deacetylase inhibitors for prostate cancer therapyKhandelwal, Aakanksha; Njar, Vincent (2007)All-trans-retinoic acid (ATRA), a metabolite of vitamin A, is 5 to 8 times lower in prostate carcinoma tissue when compared to a normal prostate and benign prostatic hyperplasia. ATRA plays a major role in a number of biological processes and is metabolized by cytochrome P450 enzymes into inactive polar metabolites. The anticancer effects of a novel class of agents called atypical retinoic acid metabolism blocking agents (RAMBAs) were examined in combination with histone deacetylase inhibitors (HDACIs). The purpose of this study was to select combinations of agents which would have potent anti-cancer activities in a hormone insensitive prostate cancer model. One particular RAMBA, VN/66-1 which displays favorable pharmacokinetics and minimal toxicity was found to be highly potent in inhibiting PC-3 cell growth. Two HDACIs, SAHA and MS-275 were also found to be potent in inhibiting PC-3 cell viability. The combinations of VN/66-1 + MS-275 and VN/66-1 + SAHA synergistically inhibited PC-3 cell growth caused cytotoxicity/cytostaticity. Treatment of PC-3 xenografts with VN/66-1 (10 mg/kg/day) + MS-275 (2.5 mg/kg/day) for 18 days resulted in an 85% reduction in final mean tumor volume compared with control. The combination of VN/66-1 + SAHA, however, did not reduce tumor growth as effectively as the two agents individually most likely due to too low doses. The data obtained suggest that the mechanism of action of the combination of VN/66-1 + MS-275 is through apoptosis and DNA damage-induced p21 WAF1/CIP1 activation. Active p21 is involved in the inhibition of the cdc2-cyclin B1 complex resulting in eventual G2/M phase arrest. This induction of p21 is also in part due to the enhancement of acetylation of histones H3 and H4 which is also responsible for the activation of tumor suppressor gene RARbeta2, the latter which also plays a role in mediating cell death. Up-regulation of Bad and down-regulation of Bcl-2 as well as PARP cleavage indicated that apoptosis via the intrinsic pathway is also contributing to cell death. Together, these results suggest that VN/66-1 or its combination with MS-275 may be a novel therapy for the treatment of hormone refractory prostate carcinoma.
-
NEU1 Sialidase Promotes MUC1 Ectodomain Release from Human Airway Epithelial Cells as a Soluble Decoy Receptor that Blocks Pseudomonas aeruginosa AdhesionLillehoj, Erik P.; Guang, Wei; Hyun, Sang Won; Luzina, Irina G.; Atamas, Sergei P.; Verceles, Avelino C.; Goldblum, Simeon E. (2015)